JP2016512199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512199A5 JP2016512199A5 JP2015561627A JP2015561627A JP2016512199A5 JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5 JP 2015561627 A JP2015561627 A JP 2015561627A JP 2015561627 A JP2015561627 A JP 2015561627A JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- pharmaceutical composition
- cell surface
- surface molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 241000700562 Myxoma virus Species 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| PCT/US2014/020935 WO2014138314A1 (en) | 2013-03-05 | 2014-03-05 | Oncolytic virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512199A JP2016512199A (ja) | 2016-04-25 |
| JP2016512199A5 true JP2016512199A5 (https=) | 2017-04-06 |
Family
ID=50424733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561627A Pending JP2016512199A (ja) | 2013-03-05 | 2014-03-05 | 腫瘍溶解性ウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160000842A1 (https=) |
| EP (1) | EP2964241A1 (https=) |
| JP (1) | JP2016512199A (https=) |
| CN (1) | CN105407902A (https=) |
| CA (1) | CA2903096A1 (https=) |
| WO (1) | WO2014138314A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| JP2017529851A (ja) * | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| AU2016232009B2 (en) * | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| EP3217993A1 (en) * | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| CA3070146A1 (en) * | 2016-07-19 | 2018-01-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting stat3 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL303187A (en) * | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| JP7138946B2 (ja) | 2016-09-27 | 2022-09-20 | セイター セラピューティクス エルエルシー | 最適化された腫瘍溶解性ウイルスおよびその使用 |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| JP7724601B2 (ja) * | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
| GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
| CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
| EP3731850A4 (en) * | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| SG11202007961QA (en) * | 2018-04-13 | 2020-09-29 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
| CA3099308A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| WO2020017962A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| CA3133410A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
| JP7704419B2 (ja) * | 2019-06-27 | 2025-07-08 | バイオノックス インコーポレイテッド | 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| EP3957650A1 (en) * | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| JP2024506249A (ja) | 2021-01-22 | 2024-02-13 | メンドゥス・ベスローテン・フェンノートシャップ | 腫瘍ワクチン接種の方法 |
| CN115161293B (zh) * | 2021-04-01 | 2024-11-15 | 南京惟亚德生物医药有限公司 | 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用 |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| RU2008129827A (ru) * | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| WO2014138306A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
-
2014
- 2014-03-05 WO PCT/US2014/020935 patent/WO2014138314A1/en not_active Ceased
- 2014-03-05 CA CA2903096A patent/CA2903096A1/en not_active Abandoned
- 2014-03-05 CN CN201480025597.3A patent/CN105407902A/zh active Pending
- 2014-03-05 EP EP14714851.4A patent/EP2964241A1/en not_active Ceased
- 2014-03-05 JP JP2015561627A patent/JP2016512199A/ja active Pending
- 2014-03-05 US US14/770,061 patent/US20160000842A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512199A5 (https=) | ||
| JP2016514956A5 (https=) | ||
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Martin et al. | Oncolytic virus combination therapy: killing one bird with two stones | |
| Fang et al. | NK cell-based immunotherapy for cancer | |
| JP2019519245A5 (https=) | ||
| JP2017029157A5 (https=) | ||
| RU2019102391A (ru) | Доставка терапевтических полипептидов посредством псевдотипированных онкологических вирусов | |
| JP2018512047A5 (https=) | ||
| JP2019513118A5 (https=) | ||
| JP2012136541A5 (https=) | ||
| JP2018527952A5 (https=) | ||
| JP2019536806A5 (https=) | ||
| RU2017103151A (ru) | Комбинация онколитического вируса с модуляторами иммунологических контрольных точек | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| JP2008056679A5 (https=) | ||
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| EP3812401A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof | |
| PH12016500859B1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| JP2014532649A5 (https=) | ||
| JP2019525898A5 (https=) | ||
| Rahim et al. | Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine | |
| JP2016104790A5 (https=) | ||
| JP2012523417A5 (https=) | ||
| JP2018023397A5 (https=) |